机构：[1]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.临床科室呼吸内科河北医科大学第四医院[2]Department of Pulmonary and Critical Care Medicine, Hebei PetroChina Center Hospital, Langfang, P.R. China.
Currently, immune checkpoint inhibitors (ICIs) therapy is one of the main methods of treatment in non-small cell lung cancer (NSCLC). This study aimed to explore the risk factors of VTE and evaluate the effect of ICIs on VTE in patients with NSCLC.We retrospectively studied patients with NSCLC who were divided into VTE group and without VTE (Non-VTE) group. We identified the risk factors of VTE in NSCLC patients and evaluated the effect of ICIs on VTE in NSCLC patients.We found that clinical stage III-IV (P = 0.015) and Khorana score (KS) ≥ 2 (P = 0.047) were independent risk factors for the occurrence of VTE in NSCLC, and treatment with ICIs reduced the risk of VTE occurrence (P = 0.028). There were no differences of survival rates in the 12-month (P = 0.449), 24-month (P = 0.412), or 36-month (P = 0.315) between the VTE and non-VTE groups. History of anti-angiogenic therapy (P = 0.033) and chronic obstructive pulmonary disease (COPD) (P = 0.046) were independent risk factors for VTE in NSCLC patients who were treated with ICIs.This study suggests that we should strengthen anticoagulant therapy when using ICIs for NSCLC patients with a history of anti-angiogenic therapy and COPD.
基金：
This work was supported by Hebei provincial health technology project [20210471], and prevention and treatment of geriatric diseases by Hebei provincial department of finance [20200316]
第一作者机构：[1]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.[*1]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P.R. China
推荐引用方式(GB/T 7714)：
He Xin,Wei Shan-Na,Qin Wen-Wen,et al.Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients[J].EXPERT REVIEW OF HEMATOLOGY.2023,16(12):1135-1142.doi:10.1080/17474086.2023.2276209.
APA：
He Xin,Wei Shan-Na,Qin Wen-Wen,Geng Nan,Li Bin...&Wang Ping.(2023).Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.EXPERT REVIEW OF HEMATOLOGY,16,(12)
MLA：
He Xin,et al."Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients".EXPERT REVIEW OF HEMATOLOGY 16..12(2023):1135-1142
：